Elicio Therapeutics Reports $10.1 Million Net Loss in Q3 2025, Decreasing from Previous Year

Elicio Therapeutics, Inc. reported a net loss of $10.1 million for the third quarter of 2025, a significant decrease from the $18.8 million loss recorded in the same period of 2024. For the nine months ending September 30, 2025, the company’s net loss was $31.9 million, down from $37.9 million in the prior year. The reduction in losses is attributed to a decrease in operating expenses, which totaled $8.0 million for the quarter, compared to $10.3 million in the previous year, primarily due to lower research and development costs as clinical trials progressed. Research and development expenses were $5.0 million for the quarter, down 30% from $7.2 million in 2024, while general and administrative expenses remained relatively stable at $3.0 million.

Elicio's financial position showed improvement, with cash and cash equivalents increasing to $20.6 million as of September 30, 2025, compared to $17.6 million at the end of 2024. The company’s total assets were reported at $28.3 million, slightly up from $28.2 million at the end of the previous fiscal year. Total liabilities decreased significantly from $39.5 million to $24.5 million, primarily due to a reduction in long-term debt and accrued expenses. The company’s accumulated deficit reached $226.0 million, reflecting ongoing investments in its clinical pipeline.

Strategically, Elicio is advancing its lead product candidate, ELI-002 7P, which is currently in a Phase 2 clinical trial targeting mutant KRAS pancreatic cancer. The Independent Data Monitoring Committee recently recommended that the trial continue without modifications, confirming a favorable safety profile. The company is also exploring additional product candidates, including ELI-007 and ELI-008, which are in preclinical studies. Elicio's operational focus remains on developing immunotherapies that can effectively stimulate immune responses in cancer patients.

In terms of financing, Elicio has raised approximately $214.8 million since its inception through various means, including public offerings and private placements. The company anticipates needing additional capital to fund its operations beyond the second quarter of 2026, as it continues to incur substantial expenditures related to product development and regulatory approvals. Elicio plans to address its funding needs through equity offerings, debt financing, and potential collaborations, although it acknowledges the uncertainty surrounding the availability of such financing.

Looking ahead, Elicio expects to continue incurring net losses as it invests in the development of its product candidates. The company is focused on advancing its clinical trials and expanding its pipeline, while also managing its cash flow to ensure operational sustainability. The outlook remains cautious, with the company emphasizing the need for additional capital to support its ongoing activities and mitigate the risks associated with its business model.